

OPEN ACCESS

Full open access to this and thousands of other papers at <http://www.la-press.com>.

Erratum in: Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib

Takuya Araki^{1,2}, Hideaki Yashima^{1,2}, Kimihiro Shimizu³, Tohru Aomori^{1,2,4}, Tadahiro Hashita², Kyoichi Kaira⁵, Tomonori Nakamura^{1,2} and Koujiro Yamamoto^{1,2}

¹Department of Clinical Pharmacology, Gunma University Graduate School of Medicine, Maebashi, Japan.

²Department of Pharmacy, Gunma University Hospital, Maebashi, Japan. ³Department of Thoracic and Visceral Organ Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan. ⁴Center for Medical Education, Gunma University Graduate School of Medicine, Maebashi, Japan. ⁵Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi, Japan. Corresponding author email: tkyaraki@gunma-u.ac.jp

This article (Clinical Medicine Insights: Oncology. 2012;6:407–21. doi: 10.4137/CMO.S7340) is corrected at the request of the original authors. Table 2 contains an error.

The table compares gefitinib to placebo in the INTEREST trial. In this trial, gefitinib was compared to Docetaxel and not placebo.

Clinical Medicine Insights: Oncology 2013;7 85

doi: [10.4137/CMO.S11910](https://doi.org/10.4137/CMO.S11910)

This article is available from <http://www.la-press.com>.

© the author(s), publisher and licensee Libertas Academica Ltd.

This is an open access article published under the Creative Commons CC-BY-NC 3.0 license.